All News
FAPI PET/CT entheseal & synovial fibroblast activation predicts PsA in high risk PsO better than MUS @RheumNow #EULAR2024 https://t.co/uqmEvMg9WN
Peter Nash drpnash ( View Tweet)
more evidence in PsA - switch MOA rather than cycle within class failed first TNF @RheumNow #EULAR2024 https://t.co/hf2UB5MXEy
Peter Nash drpnash ( View Tweet)
opposing point of view especially in males at 3 years !@RheumNow #EULAR2024 https://t.co/CXxIScQbFD
Peter Nash drpnash ( View Tweet)
New #JAKi #disease #results
#Baricitinib in #alopecia #areata esp 4mg/d
#Upadacitinib in Crohn’s
#Upa in #polyarticular #JIA & kid #PsA
+RCT of UPA in #GCA
Awaiting results of #SLE
With #deucravicitinib & UPA #RCTs
#EULAR2024 @eular_org @RheumNow
Janet Pope Janetbirdope ( View Tweet)
Do we give enough attention to pts mental health?
2 cohort 400+ RA tREACH & DEPAR 500+ PsA
RA 20% depression 30% anxiety
PsA 19% depression 22% anxiety
2 yrs no remission
RA OR 2.5 depression OR 1.7 anxiety
PsA OR 6.10 depression OR 4.67 anxiety
@RheumNow #EULAR2024 POS0946 https://t.co/ok4HRNJqgY
Aurelie Najm AurelieRheumo ( View Tweet)
Cycle or swap 2? Post failure to a first TNFi in patients with PsA, there was no difference in cycle versus swap to IL17i for drug retention rate or disease activity. In male PsA patients a cycle strategy had a longer drug retention rate compared to a swap (IL-17i) strategy.… https://t.co/5BykvDwFWV https://t.co/GfcnIltV2A
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
What is better in #PsA
#psoriatic #arthritis
#TNFi or #apremilast #PDE4i
#COREVITAS database study in #PsA
YOU can guess the answer!
1st line advanced RxTNFi lasts longer - retention
Vs PDE4i
#EULAR2024 @RheumNow @eular_org
POS0990 https://t.co/VmYG6Rj87c
Janet Pope Janetbirdope ( View Tweet)
Cycle or Swap? The swap strategy (SG) (i.e. from TNFi to IL17i) had higher retention rates compared to the change strategy (CG) choice in PsA patients who failed the first line of advanced treatment. The 5 years retention rate in SG was higher than in CG (57,8% vs 45,2%; p=0.1).… https://t.co/pH5rFI00vK https://t.co/XqTHO1tIr3
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Discovery in joint and skin disease - PsA
Three different clusters #EULAR2024 @RheumNow https://t.co/Nj5HZOVqas
Bella Mehta bella_mehta ( View Tweet)
The age old question in #inflammatory #arthritis
Should you cycle within TNFi class or move on to another MOA in
#PsA #psoriatic #arthritis
Better retention to go to a IL17i vs another TNFi in observational study comparing the 2
POS0266
#EULAR2024 @RheumNow @eular_org https://t.co/CXcmYAG4m9
Links:
Janet Pope Janetbirdope ( View Tweet)
Can you predict which pts with
#PsA
#psoriatic #arthritis
Will respond to #TNFi #Rx?
Well, 🤔 maybe
Needs validation and an easy reliable inexpensive biomarker!
#EULAR2024 @RheumNow @eular_org
POS0992 https://t.co/Ce92561AMO
Links:
Janet Pope Janetbirdope ( View Tweet)
PsA: one composite index that does it all
cDAPSA + Investigator’s Global Assessment (IGA) of PSO
Cohen’s kappa 0.72 & 88% concordance with PASDAS LDA
88% sensitivity & specificity in DISCOVER-1 & 2 trial data
#EULAR2024 @RheumNow POS0254 https://t.co/ZBb1M4IusC
Aurelie Najm AurelieRheumo ( View Tweet)
🚨 New 68Ga-FAPI-04-PET/CT, fibroblast activation tracer
38 PSO patients w/ arthralgia
Correlation PET/CT SUVmax, TJC & tender enthesis count
68Ga-FAPI-04 uptake = higher risk developing PsA 6mo
Shows signs of inflammation before MSUS!
#EULAR2024 @RheumNow POS0242 https://t.co/GG6qeD4qJn
Aurelie Najm AurelieRheumo ( View Tweet)
This can be coming to a clinic near you. Hotspot/ROI ratio (HRR) values from high-resolution thermographic marker in the detection of joint inflammation, compared to joint ultrasound showed excellent performance in the differentiation of joints with US inflammatory activity from… https://t.co/1unRxxgHAd https://t.co/tOPDSxzvwB
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Did the patient fail on therapy or are the therapies failing the patient? 🤔
Difficult to to manage psoriatic arthritis: A suggested approach
#EULAR2024
NZ https://t.co/lYvXEX7dp3
Annals of the Rheumatic Diseases ARD_BMJ ( View Tweet)
New drug TAK-279 (zasocitinib) shows promise for #PsA Significantly improved symptoms in patients after 12 weeks compared to placebo & well-tolerated.
Fewer targeted oral therapies exist, making zasocitinib a potential new option. #EULAR24 #PsA
IH https://t.co/RvcONHCLvz
Annals of the Rheumatic Diseases ARD_BMJ ( View Tweet)
Swedish/Danish cohort study in PsA
17000+ bionaïve 8000+ TNFi & 2000+ other MoA
Overall non melanoma skin cancer rate 651
(505 BCC & 87 SCC)
TNFi treated pts:
HR 1.25 NMSC vs. bionaive (95CI 1.04 to 1.50)
HR 1.19 NMSC vs. other MoA (ns)
#EULAR2024 @RheumNow AbstOP0150 https://t.co/DVj8l7yFR6
Aurelie Najm AurelieRheumo ( View Tweet)
TYK2i RCT 290 pts 12 wks in active PSA
TAK-279 15mg 30 mg 53% 54% vs PBO 29%
ACR 50 15mg 30 mg 26% 26% vs. PBO 10%response PASI 75 30 mg 46% vs. 15m 28% PBO 15%
Safety profile acceptable
Abstr#OP0138 #EULAR2024 @RheumNow https://t.co/thNuwvUgQp
Aurelie Najm AurelieRheumo ( View Tweet)
12-week ARGO Phase 2 trial data of IL-17A- and IL-17F-inhibiting Nanobody sonelokimab delivers rapid onset and robust levels of clinical response, including high-threshold outcomes, compared with placebo in patients with active PsA, with a favorable benefit–risk profile. It met… https://t.co/4wj222FkzP https://t.co/ipUSjKvpuB
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Combination of GOL/MTX was not significantly superior in reducing PASDAS-measured disease activity at 24 weeks. First line treatment of early, DMARD naïve PsA with MTX 25 mg/week and CS produced effective disease control. There was low utilisation of bDMARDs at 52 weeks in both… https://t.co/aEg9rw4evM https://t.co/prDtnHm793
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
